Skip to content

Study to access the treatment adherence, tolerability & safety of Ayurveda treatment in the management of Knee Osteoarthritis.

Treatment adherence, tolerability & safety of Ayurveda therapeutic regimen in the management of Primary Knee Osteoarthritis: An OPD-based study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/054503
Enrollment
480
Registered
2023-06-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee

Interventions

None listed

Sponsors

CENTRAL COUNCIL FOR RESEARCH IN AYURVEDIC SCIENCE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient fulfilling the following- 1.American College of Rheumatology (ACR) functional status criteria class I, II and III (Pain in knee + Any three of the following: a. Age > 50 years b. less than 30 minutes of stiffness c. crepitus •bony tenderness •bony enlargement •no palpable warmth 2.Able and willing to give informed consent

Exclusion criteria

Exclusion criteria: 1.Grade 3 and above radiographic changes in the affected knee (Kellgren-Lawrence classification) 2.ignificant trauma to the knee including arthroscopy within preceding one year 3.History of knee joint replacement 4.BMI>=30 kg/m² 5.History of prior intra-articular corticosteroid or hyaluronic acid administration within one month of the study 6.Patient taking corticosteroids 7.Patient with history of Rheumatoid arthritis, Psoriatic arthritis, Psoriatic arthritis, or any other type of inflammatory arthritis 8.Patients with uncontrolled Diabetes Mellitus (HbA1c >8.0). 9.History of hepatic disorders (more than three times upper normal limit of normal of liver enzymes) or renal disorders (serum creatinine > 1.2 mg %) 10.History or active malignancy 11.Hypersensitivity to study interventions 12.Any other disease condition that in the opinion of the investigator may compromise the participantâ??s safety or compliance

Design outcomes

Primary

MeasureTime frame
â?¢Assessment of treatment adherence through self-reported compliance log & used medication containers/strips â?¢Assessment of the tolerability of the Ayurveda therapeutic regimen through reported incidence of adverse events (GIT-related AE specifically) during the study period (Time frame: day 30, 60, 90, 120, 150, 180) â?¢Change in the laboratory safety parameters from baseline (CBC, LFT, KFT) (Time frame: baseline, day 90, 180)Timepoint: Day 30, 60, 90, 120, 150, 180

Secondary

MeasureTime frame
â?¢ Change in WOMAC index score for pain, stiffness & physical function from baseline (Time frame: day 30, 60, 90, 120, 150, 180) â?¢ Change in the score of Numeric Pain rating scale from baseline(Time frame: day 30, 60, 90, 120, 150, 180) â?¢ Change in health related quality of life from baseline assessed through SF-12 questionnaire (Time frame: day 30, 60, 90, 120, 150, 180) â?¢ Change in the need of Rescue Analgesic medication (Time frame: day 30, 60, 90, 120, 150, 180)Timepoint: Day 30, 60, 90, 120, 150, 180

Countries

India

Contacts

Public ContactDr Amit Madan

Central Ayurveda Research Institute

dr.madan.amit@gmail.com7027952029

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026